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Background: Spinocerebellar ataxia type 7 (SCA7) is one of nine inherited neurodegenerative disorders caused by
polyglutamine (polyQ) expansions. Common mechanisms of disease pathogenesis suggested for polyQ disorders
include aggregation of the polyQ protein and induction of oxidative stress. However, the exact mechanism(s) of
toxicity is still unclear.
Results: In this study we show that expression of polyQ expanded ATXN7 in a novel stable inducible cell model
first results in a concomitant increase in ROS levels and aggregation of the disease protein and later cellular toxicity.
The increase in ROS could be completely prevented by inhibition of NADPH oxidase (NOX) complexes suggesting
that ATXN7 directly or indirectly causes oxidative stress by increasing superoxide anion production from these
complexes. Moreover, we could observe that induction of mutant ATXN7 leads to a decrease in the levels of
catalase, a key enzyme in detoxifying hydrogen peroxide produced from dismutation of superoxide anions. This
could also contribute to the generation of oxidative stress. Most importantly, we found that treatment with a
general anti-oxidant or inhibitors of NOX complexes reduced both the aggregation and toxicity of mutant ATXN7.
In contrast, ATXN7 aggregation was aggravated by treatments promoting oxidative stress.
Conclusion: Our results demonstrates that oxidative stress contributes to ATXN7 aggregation as well as toxicity and
show that anti-oxidants or NOX inhibition can ameliorate mutant ATXN7 toxicity.
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Spinocerebellar ataxia type 7 (SCA7) is an autosomal
dominant inherited neurodegenerative disorder charac-
terized by cerebellar ataxia and visual problems due to a
progressive loss of neurons within the cerebellum, retina
and brainstem [1,2]. Expansion of an unstable CAG re-
peat in the first coding exon of the SCA7 gene, resulting
in an expanded polyglutamine domain in the N-terminal
of the ataxin-7 (ATXN7) protein causes the disease [3].
The ATXN7 protein is widely expressed in the nervous
system [4-6] and is a subunit of the STAGA (SPT3-TAF
(II)31-GCN5L acetylase) complex [7,8].* Correspondence: anna-lena.strom@neurochem.su.se
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reproduction in any medium, provided the orTo date, nine disorders including Huntington’s disease
(HD), dentatorubral and pallidoluysian atrophy (DRPLA),
spinobulbar muscular atrophy (SBMA) and six forms of
Spinocerebellar ataxias (SCA1-3, 6, 7 and 17) caused by
expanded polyglutamine domains have been identified, for
review see [9]. These disorders are commonly known as
polyglutamine (polyQ) diseases and are characterized by
the aggregation of the expanded polyQ protein. Mutant
ATXN7 has been shown to aggregate and form inclusions
in both patients and cell models [5,6,10]. A correlation be-
tween the ability of polyglutamine proteins to aggregate
and toxicity has been shown, however, whether misfolded
monomers, oligomers or large inclusions formed during
the aggregation process are the major toxic species is still
unclear [11-13].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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exceed the capacity of the cell’s endogenous anti-oxidant
systems and result in damage to cellular components
like DNA, lipids and proteins [14]. Prolonged oxidative
stress can lead to cell death and this pathway has been
implicated in many neurodegenerative diseases including
Alzheimer’s disease (AD), Parkinson’s disease (PD) and
amyotrophic lateral sclerosis (ALS), for review see
[15,16]. Oxidative stress has also been implicated in
polyglutamine diseases, for instance Huntington’s dis-
ease, DRPLA and SCA1 [17-20]. ROS (reactive oxygen
species) is a major type of free radicals in cells and is
normally produced during oxidative phosphorylation in
mitochondria [14]. Up to 2% of the electrons passing the
electron transport chain escape and reacts with molecu-
lar oxygen to yield ROS. Due to their high metabolic
rate neurons are exposed to high levels of ROS [14].
Other sources of ROS is NADPH oxidase (NOX) com-
plexes and enzymes like xanthine oxidase, lipooxygenase
and cyclooxygenase [21]. NOX complexes produce
superoxide anions and are present in neurons as well as
astrocytes and microglia [22]. To prevent damage from
excess ROS, neurons and other cells have an extensive
anti-oxidant defense system made up of several enzymes
and small molecules [23]. Enzymes with anti-oxidant
function include glutathione transferases (GSTs), super
oxide dismutases (SODs), superoxide reductase, catalase
(CAT), peroxiredoxins (Prxs) and glutathione peroxi-
dases (Gpxs). Glutathione (GSH) an important small
anti-oxidant molecule protects cells against oxidative
stress by conjugating with ROS in a reaction catalyzed
by GST [24]. During the conjugation reaction GSH be-
come oxidized into glutathione disulfide (GSSH) and is
thus depleted. GSH depletion have been shown to occur
in neurodegenerative disorders like Parkinson’s disease
[25]. In mammals, there are at least three forms of
SOD: a cytosolic (CuZnSOD/SOD1), a mitochondrial
(MnSOD/SOD2) and an extracellular (ECSOD/SOD3)
form. SOD enzymes catalyze the dismutation of super-
oxide, a primary ROS, into hydrogen peroxide [26].
The hydrogen peroxide is then further converted to
water and oxygen by CAT, Prxs or Gpxs [14,27].
In this study, we show that oxidative stress plays a
major role in ATXN7-induced toxicity using a new
stable inducible PC12 cell model. We found that induc-
tion of mutant ATXN7Q65-GFP expression led to a
concomitant increase in ROS levels and aggregation of
the disease protein followed by decreased cell viability a
few days later. Analysis of some key anti-oxidant defense
enzymes revealed decreased levels of catalase, which
could contribute to decreased clearance of ROS. Fur-
thermore, inhibition of NOX complexes prevented the
increase in ROS and ameliorated aggregation suggesting
that mutant ATXN7 increase the ROS levels byactivating this complex. Moreover, supporting the cells
through application of exogenous anti-oxidants or in-
hibition of NOX complexes ameliorated AXTN7Q65
induced toxicity.
Results
Expression of mutant ATXN7 leads to oxidative stress
followed by toxicity in an inducible SCA7 PC12 cell model
To study the impact of mutant ATXN7 on cellular func-
tions we used two recently generated stable inducible
PC12 cell lines expressing N-terminal FLAG- and C-
terminal GFP-tagged ATXN7 with 10 (FLQ10 line) or 65
(FLQ65 line) glutamines [28]. In these cell lines the ex-
pression of the corresponding transgenic proteins named
ATXN7Q10-GFP and ATXN7Q65-GFP is controlled by
the Tet-off expression system and induced by removal of
doxycycline from the cell culture media. The induction
timing, expression levels and sub-cellular localization of
the transgenic ATXN7-GFP proteins have previously
been extensively characterized and showed not to differ
in these two cell lines [28]. Immunoblotting with an
ATXN7 antibody revealed weak expression after three
days of induction, but clear expression of both con-
structs from day 6 onwards (Figure 1A and [28]. No
ATXN7 aggregation was detected in ATXN7Q10-GFP
expressing cells [28]. However, in cells expressing
ATXN7Q65-GFP filter trap analysis revealed aggregation
from day 3 onwards and from day 9 the level of aggre-
gated ATXN7 material was stable (Figure 1B and [28]).
Analysis of cell viability/toxicity revealed a progressive
decrease in viability and increased toxicity as expression
of ATXN7Q65-GFP was induced, see Figure 1C-D. A
significant decrease in viability was observed from day 9
after induction using the WST-1 viability assay
(Figure 1C). In accordance with this a statistical increase
in toxicity, measured as membrane leakage, could also
be observed on day 9 after induction (Figure 1D). In
contrast, expression of the ATXNQ10-GFP protein did
not result in any significant change in cell viability or
toxicity on any day (Figure 1C-D). To establish whether
induction of oxidative stress by ATXN7Q65-GFP could
play a role in the decreased cell viability, we measured
total cellular ROS levels at various time points after in-
duction of ATXN7Q65-GFP expression. We found that
the ROS levels increased in a time dependent manner
after induction of ATXN7Q65-GFP expression
(Figure 1E). A significant increase in ROS was first
observed at day 6, prior to the decrease in viability of
the ATXN7Q65-GFP expressing cells. In contrast, ex-
pression of ATXNQ10-GFP protein did not result in any
significant change in total cellular ROS levels
(Figure 1E). As a positive control increased levels of
ROS could be observed in both FLQ10 and FLQ65 cells
after treatment with hydrogen peroxide (Figure 1E).
Figure 1 Expression of ATXN7Q65-GFP leads to increased ROS levels prior to toxicity. A) Western blot analysis of ATXN7 in FLQ10 and
FLQ65 stable PC12 cell lines induced to express GFP-tagged ATXN7 with 10 (ATXN7Q10-GFP, top panel) or 65 (ATXN7Q65-GFP, lower panel)
glutamines for the indicated number of days. Actin was used as loading control. B) Analysis of ATXN7 aggregation in FLQ65 cells induced to
express ATXN7Q65-GFP for 1–12 days using the filter trap assay. C) Viability measured by the WST-1 assay and normalized against the protein
content in FLQ10 and FLQ65 cells induced to express ATXN7Q10-GFP or ATXN7Q65-GFP for the indicated number of days. D) Toxicity measured
by the LDH membrane leakage assay in FLQ10 and FLQ65 cells induced to express ATXN7Q10-GFP or ATXN7Q65-GFP for the indicated number
of days. E) Total cellular ROS levels measured using DCHF-DA in cells induced to express ATXN7Q10-GFP or ATXN7Q65-GFP for 0–12 days. F)
Analysis of GSH levels in cells induced (−Dox) to express ATXN7Q65-GFP for 9 days and non-induced control cells (+Dox). For quantifications all
data are shown as means ± SEM from three independent experiments with triplicates. * p <0.05, ** p <0.01 and *** p <0.001.
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GFP resulted in an oxidative environment, we measured
the GSH level in FLQ65 cells induced to express
ATXN7Q65-GFP for nine days. A significant reduction
in the GSH level was observed (Figure 1F). Taken to-
gether, these observations suggest that expression of
ATXN7Q65-GFP results in increased ROS levels and
oxidative stress prior to any observable toxicity.
Anti-oxidant treatment rescues ATXN7Q65-GFP toxicity
To confirm that the oxidative stress conditions
induced by ATXN7Q65-GFP played a role in the
decreased cell viability, FLQ65 cells induced to ex-
press ATXN7Q65-GFP for nine days while growingin media supplemented or not supplemented with the
anti-oxidants α-tocopherol (Vitamin E) or NAC were
analyzed. Treatment with either anti-oxidant rescued
the viability of ATXN7Q65-GFP expressing cells and
there was no longer any difference in viability be-
tween non-induced and induced FLQ65 cells expres-
sing ATXN7Q65-GFP (Figure 2A and 2D). The
positive effects of the anti-oxidant treatments were
not due to changes in ATXN7 expression, as neither
treatment did alter the expression level of soluble
ATXN7Q65-GFP (Figure 2B and 2E). This result suggests
that oxidative stress is contributing to the toxicity in
SCA7 and this effect can be counteracted by application
of an anti-oxidant.
Figure 2 Antioxidant treatment rescues cells from ATXN7Q65-GFP induced toxicity and decrease ATXN7 aggregation. A) Viability
measured by WST-1 in FLQ65 cells not induced (+Dox) or induced (−Dox) to express ATXN7Q65-GFP for 9 days while growing in media with or
without 1 μM Vitamin E (α-tocopherol). B) Analysis and quantification of soluble ATXN7Q65-GFP by western blot in FLQ65 cells grown and
treated as in A. C) Analysis and quantification of ATXN7 aggregation by filter trap assay in FLQ65 cells grown and treated as in A. D) Viability in
cells grown as in A but treated with or without 5 mM NAC. E) Analysis and quantification of soluble ATXN7Q65-GFP by western blot in FLQ65
cells grown and treated as in D. F) Analysis and quantification of ATXN7 aggregation by filter trap assay in FLQ65 cells grown and treated as in D.
For all western blots actin was used as loading control. For quantifications data are shown as means ± SEM from three independent experiments
with triplicates. NS: not significant, * p <0.05, ** p <0.01 and *** p <0.001.
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To investigate the relationship between oxidative stress
and ATXN7 aggregation, we analyzed whether anti-
oxidant treatment of our stable FLQ65 cells induced to
express ATXN7Q65-GFP also had an effect on the level
of ATXN7 aggregation. Results showed that both α-
tocopherol and NAC treatment during the induction ofATXN7Q65-GFP expression in the stable PC12 cell
model lowered the level of aggregated ATXN7 material
with circa 40–80% (Figure 2C and 2F). To further con-
firm the connection between oxidative stress and
ATXN7 aggregation and make sure that the effect seen
in Figure 2 was not influenced by the GFP-tag on
ATXN7 or specific to PC12 cells, we did further
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myc-tagged ATXN7 with 10 (ATXN7Q10-myc) or 65
(ATXN7Q65-myc) glutamines. We first investigated
whether support of the anti-oxidant system could also
ameliorate the aggregation of ATXN7Q65-myc, by co-
transfecting the HEK 293 T cells with ATXN7Q65-myc
and RORα or SOD1. Over-expression of RORα, a tran-
scription factor known to activate anti-oxidant genes
[29], ameliorated the aggregation of ATXN7Q65-Myc
(Figure 3A). So did over-expression of wild-type SOD1
with full dismutase activity, whereas co-expression of
mutant forms of SOD1 with reduced (A4V) [30,31] or
no enzymatic activity (H48Q) [31] showed reduced or
no ability, respectively, to reduce ATXN7Q65-Myc aggre-
gation (Figure 3B). Neither RORα nor SOD1 co-
expression affected the expression of soluble ATXN7Q65-Figure 3 RORα and SOD1 reduce ATXN7Q65-Myc protein aggregation
RORα. After 48 hours RORα and ATXN7Q65-Myc expression (left panel) and
was used as loading control for western blots. B) HEK 293 T cells were co-t
wild-type (WT), A4V mutant or H48Q mutant SOD1. Empty vector (Myc) wa
each well. Forty-eight hours after transfection ATXN7Q65-Myc aggregation
A4V SOD1 (middle) and H48Q SOD1 (right). All quantifications are shown a
NS: not significant, * p <0.05 and ** p <0.01.Myc (Figure 3A and data not shown). We next investi-
gated whether promotion of an oxidative environment
could aggravate the aggregation of ATXN7Q65-myc by
treating transfected HEK 293 T cells with increasing
concentrations of H2O2 (Figure 4A-B) or BSO
(Figure 4C-D) an inhibitor of GSH biosynthesis [32].
No trace of aggregated material could be detected in
ATXN7Q10-Myc expressing cells under control or
treated conditions (data not shown). However, aggre-
gated ATXN7 material was detected in ATXN7Q65-
Myc cells and both H2O2 and BSO treatment led to an
increase in aggregated material without affecting the
expression of soluble ATXN7Q65-Myc (Figure 4).
Taken together, these data suggest that there is a clear
connection between oxidative stress and aggregation of
mutant ATXN7.. A) HEK 293 cells were co-transfected to express ATXN7Q65-Myc and
ATXN7 aggregation (right panel) were analyzed and quantified. Actin
ransfected with ATXN7Q65-Myc and 0–1 μg of a plasmid encoding
s used to allow the same amount of plasmids to be transfected in
was analyzed by filter trap in cells co-transfected with WT SOD1 (left),
s means ± SEM from three independent experiments with triplicates.
Figure 4 Oxidative stress increases aggregation of ATXN7Q65-Myc. A) HEK 293 cells transfected to express ATXN7Q10-myc or ATXN7Q65-
myc was treated with 0–0.5 mM H2O2 for 48 h and ATXN7 levels were analyzed by western blot. Upper panel; a representative western blot,
lower panel: quantification of ATXN7 expression levels. B) Analysis of aggregated ATXN7 in cells transfected and treated as in A. Upper panel; a
representative blot, lower panel; quantification of ATXN7 aggregation. C) HEK 293 cells transfected as in A was treated with 0–2 mM BSO for 48 h
and western blot performed. Upper panel; a representative western blot, lower panel; quantification of ATXN7 expression levels. D) Analysis of
aggregated ATXN7 in cells treated as in C. Upper panel; a representative blot, lower panel; quantification of ATXN7 aggregation. Actin was used
as loading control in all western blot experiments. All quantitative data are shown as means ± SEM from three independent experiments with
triplicates. NS: not significant, * p <0.05, ** p <0.01 and *** p <0.001.
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expression levels of some key anti-oxidant enzymes
Mutant ATXN7 could induce oxidative stress by interfer-
ing with the anti-oxidant defense system or by causing an
increase in free radical production. To investigate the sta-
tus of the anti-oxidant defense system, we analyzed the ex-
pression levels of some key anti-oxidant enzymes;
Glutathione transferase A3 (GSTA3), SOD1 and CAT in
our stable PC12 model. After induction of ATXN7Q65-
GFP, the expression levels of GSTA3 and SOD1 showed a
progressively increasing trend with statistical differences in
expression at day 9 and/or 12 after induction (Figure 5A-
C). In contrast, the expression level of CAT showed a de-
creasing trend after induction of ATXN7Q65-GFP(Figure 5A and 5D). We also investigated whether anti-
oxidant treatment could prevent the change in expression
of these enzymes. Indeed, in induced FLQ65 cells grown in
NAC supplemented media for 9 days, the increase in
GSTA3 and SOD1 expression was reduced or completely
gone (Figure 5E-G). However, the decreased expression of
CAT was not restored (Figure 5H). Our results suggest that
the cell is trying to cope with the oxidative environment by
up-regulating at least some key anti-oxidant enzymes.
Increased ROS production from NOX complexes in
ATXN7Q65-GFP expressing cells
Mitochondria are a major source of ROS and damage
to mitochondria resulting in increased mitochondrial
Figure 5 (See legend on next page.)
Ajayi et al. BMC Neuroscience 2012, 13:86 Page 7 of 14
http://www.biomedcentral.com/1471-2202/13/86
(See figure on previous page.)
Figure 5 Reduced CAT levels, but increased levels of SOD1 and GSTA3 in ATXN7Q65-GFP expressing cells. A) Representative western blot
analysis of GSTA3, SOD1 and CAT levels in FLQ65 cells induced to express ATXN7Q65-GFP for 0–12 days. B) Quantitative analysis of GSTA3 levels
from three experiments as shown in A. C) Quantitative analysis of SOD1 levels from three experiments as shown in A. D) Quantitative analysis of
CAT levels from three experiments as shown in A. E) NAC effect on the expression of GSTA3, SOD1 and CAT levels in ATXN7Q65-GFP expressing
cells. FLQ65 cells not induced or induced to express ATXN7Q65-GFP for 9 days while growing in media with or without NAC (5 mM) were
analyzed. F) Quantitative analysis of GSTA3 levels from three experiments with treatments as in E. G) Quantitative analysis of SOD1 levels from
three experiments with treatments as in E. H) Quantitative analysis of CAT levels from three experiments with treatments as in E. All
quantifications are shown as means ± SEM from three independent experiments with triplicates. * p <0.05, ** p <0.01 and *** p <0.001.
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neurodegeneration. To investigate whether this mechan-
ism plays a role in the elevation of the ROS levels in our
ATXN7Q65-GFP expressing cells, we measure the level
of mitochondrial superoxide anions at various time
points after induction of ATXN7Q65-GFP expression.
No increase in mitochondrial superoxide production
could be observed at any time point after ATXN7Q65-
GFP induction (Figure 6A). Antimycin A treatment was
used as a positive control and elevated the levels of
mitochondrial ROS as expected (Figure 6A).
We then went on to investigate whether an increased
ROS production by NOX complexes contributes to the
oxidative stress environment induced by ATXN7Q65-
GFP. The level of ROS, GSH and ATXN7 aggregation,
as well as viability, was measured in FLQ65 cells induced
to express ATXN7Q65-GFP for nine days while growing
in media supplemented or not supplemented with a
NOX complex inhibitor apocynin (Apo). The apocynin
treatment completely blocked the increase in ROS, led
to a small increase in the level of GSH, reduced ATXN7
aggregation and ameliorated the toxicity in ATXN7Q65-
GFP expressing cells (Figure 6B-C). Similarly treatment
of the ATXN7Q65-GFP expressing cells with the cell-
permeable gp91ds-TAT peptide, a specific NOX complex
inhibitor [33], also decreased ROS levels and ameliorated
the toxicity (Figure 6D). In contrast, treatment with the
control peptide Scramble-TAT had no effect on ROS
levels or viability (data not shown). These results suggest
that mutant ATXN7 either directly or indirectly leads to
activation of NOX complexes resulting in increased ROS
production and oxidative stress in our cell model.Discussion
Oxidative stress has been implicated in the pathology of
several neurodegenerative diseases. In this study we
show that oxidative stress is a major contributor to ag-
gregation and toxicity of the SCA7 disease protein
ATXN7. Furthermore, our results suggest that mutant
ATXN7 could cause oxidative stress by directly or indir-
ectly reducing the levels of the anti-oxidant enzyme
CAT and increasing the ROS production through NOX
complexes. Most importantly we show that anti-oxidanttreatment or inhibition of ROS production from NOX
complexes ameliorates ATXN7 toxicity.
To study the role of oxidative stress in SCA7, we used
a new stable inducible cell model (FLQ65) in which the
expression of GFP-tagged ATXN7 with an expanded
glutamine domain (ATXN7Q65-GFP) is controlled by
the Tet-off system. In this model, clear expression and
aggregation of ATXN7Q65-GFP was detected six days
after induction (doxycycline removal from the media),
ROS levels was increased from day 6 and the cell viabil-
ity decreased from day 9 onwards. The increase in ROS
levels hence preceded cell toxicity in our model and
anti-oxidant treatment not only reduced ROS levels but
also completely rescued the viability of our cells. This
suggests that mutant ATXN7 cause toxicity by inducing
oxidative stress. Other polyglutamine proteins have also
been shown to cause elevated ROS levels and oxidative
damage to DNA and lipids have been reported in both
HD patients and animal models, for review see [34].
However, the mechanism(s) by which expanded polyglu-
tamine proteins alter the redox-homeostasis is unclear.
Increased ROS production either due to aggregating
structures functioning as centers for oxidative reactions
[35,36] or polyglutamine proteins causing damage to the
mitochondria electron transport chain [37,38] has been
suggested. In our study we saw no evidence for
increased ROS production from mitochondria. However,
we found that inhibition of NOX complexes prevented
the ATXN7Q65-GFP induced elevation of ROS and
ameliorated the ATXN7 toxicity. This is in agreement
with a recent study by Bertoni et al. [39], suggesting that
expression of an expanded polyQ stretch can lead to
NOX activation. NOX complexes have been mostly
studied in immune cells where their production of large
burst of superoxide participates in the killing of invading
microorganisms. However, NOX complexes are also
present in neurons and PC12 cells, and have been sug-
gested to regulate neurite outgrowth and neuronal activ-
ity [22,40]. SOD1 is a key enzyme for clearing away
superoxide anions and convert the radical into molecular
oxygen and H2O2 [41]. Following this dismutase reac-
tion, the H2O2, which is also reactive, is cleared away by
catalase or other enzymes like glutathione peroxidases
[42]. In our study we observed an increased expression
Figure 6 (See legend on next page.)
Ajayi et al. BMC Neuroscience 2012, 13:86 Page 9 of 14
http://www.biomedcentral.com/1471-2202/13/86
(See figure on previous page.)
Figure 6 Inhibition of NOX complexes reduces ROS production, increase the GSH level and ameliorates toxicity. A) Measurement of
mitochondrial superoxide levels using MitoSox in cells induced to express ATXN7Q65-GFP for 0, 6, 9 or 12 days. Antimycin A treatment was used
as a positive control. B) Effect of NOX complex inhibition on ATXN7Q65-GFP cells. ROS levels (top panel), GSH levels (middle panel) and cell
viability (lower panel) was analyzed in FLQ65 cells not induced (+Dox) or induced (−Dox) to express ATXN7Q65-GFP for 9 days while growing in
media with or without the NOX complex inhibitor apocynin (50 μM). C) Effect of NOX inhibition by apocynin on ATXN7 aggregation and
ATXN7Q65-GFP expression in FLQ65 cells grown and treated as in A. Top panel; representative western blot and quantification of expression.
Lower panel; representative dot blot and quantification of aggregation. D) Effect of NOX complex inhibition by gp91ds-TAT on ATXN7Q65-GFP
cells. ROS levels (top panel) and cell viability (lower panel) was analyzed in FLQ65 cells not induced (+Dox) or induced (−Dox) to express
ATXN7Q65-GFP for 9 days while growing in media with or without 10 μM of the inhibitor peptide. All quantifications are shown as means ± SEM
from three independent experiments with triplicates. NS: not significant, * p <0.05, ** p <0.01 and *** p <0.001.
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increased superoxide levels. Similarly we could observe
increased level of GSTA3, an enzymes that detoxify oxi-
datively damaged molecules for instance lipid peroxida-
tion products [24]. However, we could also observe a
decrease in the expression of catalase which could com-
promise the clearance of H2O2 and contribute to the
generation of an oxidative environment. In agreement
with our finding, decreased catalase activity have been
reported in fibroblast cultures of HD patients [43] and
decreased catalase expression was also observed in a HD
cell model by Reijonen et al [20]. However, in the Reijo-
nen study they also in contradiction to our results
observed a decrease in several other anti-oxidant
enzymes including SOD1 and SOD2 [20]. The contra-
dictory results between our study and Reijonen et al
could reflect differences between mutant huntingtin and
ATXN7 or differences in expression length and levels in
our stable model and their transient transfection model.
In fact, increased levels of several antioxidants including
SOD2, peroxiredoxins and glutathione peroxidases have
also been reported in HD patients by Sorolla et al [44].
However, comparing our results with the data from the
study by Sorolla et al also shows differences, as Sorolla
et al identified increased levels of catalase in HD brain
[44]. Again the difference between the Sorolla study and
our data could reflect differences between huntingtin
and ATXN7. It is possible that mutant ATXN7 as a sub-
unit in the co-activator complex STAGA might specific-
ally effect the regulation of catalase gene expression.
Interestingly, we could see that the decrease in catalase
levels in our mutant ATXN7 cells could not be reversed
by anti-oxidant treatment even though this prevented
the increase in ROS and reversed the changes in SOD1
and GSTA3 levels. This suggests that the mechanism by
which mutant ATXN7 effect catalase levels could be dif-
ferent than the mechanism(s) altering SOD1 and
GSTA3. Taken together, it seems clear that mutant
ATXN7 as many other polyglutamine proteins induce
oxidative stress and changes in the anti-oxidant defense
system. However, which components of the anti-oxidant
system are altered and how these alterations contributesto reduce or worsen the oxidative stress and toxicity
induced by the different polyglutamine proteins is still
more unclear and requires more investigation.
Providing anti-oxidant support have been suggested as
a potential therapeutic approach for polyglutamine dis-
ease, for review see [34]. Consistent with this idea treat-
ment with a general anti-oxidant or counteracting the
increased ROS production by inhibition of NOX com-
plexes not only ameliorated the toxicity of mutant
ATXN7, but also reduced the level of aggregated
ATXN7 in our SCA7 model. In contrast, treatment with
oxidative stress inducers (H2O2 or BSO) elevated
ATXN7 aggregation. Hence there is a strong correlation
between oxidative stress and ATXN7 aggregation. Mis-
folding and aggregation of polyQ-expanded protein is
believed to be a key step in the pathogenesis of polyQ-
diseases [45,46]. However, whether misfolded mono-
mers, oligomers or large inclusions formed during the
aggregation process are the major toxic species is still
unclear [11-13]. Furthermore, proteolytic cleavage of
several polyglutamine proteins generating more aggre-
gate prone and toxic fragments has been reported
[45,46]. In SCA7, cleavage of ATXN7 by caspase-7 at
amino acids 266 and 344 has been reported [47]. In our
model we could observe N-terminal ATXN7 fragments
[28] and these, as well as the full-length protein and
aggregated material is present at the time when we ob-
serve increase in ROS levels. Furthermore, we have seen
that full-length ATXN7 is predominately localized to the
nucleus, whereas these N-terminal fragments show a
more cytoplasmic localization [28]. Since NOX com-
plexes are mostly localized in cytoplasmic vesicles or in
the plasma membrane [22], it is tempting to speculate
that if ATXN7 activates NOX complexes through a dir-
ect interaction, then it is possibly the N-terminal mutant
ATXN7 fragments which do so either in a soluble or
aggregated form. This would be in line with the observa-
tion by Young et al. showing higher cellular toxicity by
N-terminal ATXN7 fragments [47]. Clearly future stud-
ies are needed to determine the exact mechanism and
which form of mutant ATXN7 that induces the NOX
activity.
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Taken together, our work suggests that mutant ATXN7
induce oxidative stress by reducing the level of the anti-
oxidant enzyme CAT and increasing the ROS production
from NOX complexes. We show that there is a clear
correlation between ROS levels, mutant ATXN7 aggre-
gation and decreased viability. Moreover, inhibition of
NOX complexes or treatment with an anti-oxidant can
ameliorate the mutant ATXN7 toxicity.
Methods
Plasmids
Plasmids FLQ10 and FLQ65, encoding N-terminal Flag
and C-terminal myc tagged full-length ataxin-7 referred
to as ATXN7Q10-Myc and ATXN7Q65-Myc have been
previously reported [10]. Plasmids encoding GFP-tagged
WT, A4V or H48Q SOD1 constructs as well as RORal-
pha have been previously described [10,48].
Cell culture and transfections
Generation of stable inducible PC12 cell lines expressing
N-terminal FLAG- and C-terminal GFP-tagged ATXN7
with 10 (FLQ10 line) or 65 (FLQ65 line) glutamines have
been described previously [28]. In these cell lines expres-
sion of the corresponding proteins named ATXN7Q10-
GFP and ATXN7Q65-GFP is induced upon removal of
doxycline from the media. The FLQ10 and FLQ65 stable
PC12 cell lines were grown at 37°C and 5% CO2, in
DMEM (Invitrogen) supplemented with 10% horse
serum (Invitrogen), 5% Tet System Approved fetal bo-
vine serum (PAA), 100 μg/ml G418 (Invitrogen), 100
units/ml penicillin G sodium, 100 μg/ml streptomycin
sulphate (Invitrogen), 100 μg/ml hygromycin (Invitro-
gen) and 1 μg/ml doxycycline (Sigma) when desired.
Human Embryonic Kidney 293 T (HEK 293 T) cells
were maintained in Dulbecco’s modified Eagle’s medium
(DMEM, Invitrogen) supplemented with 10% fetal bo-
vine serum (FBS, Invitrogen) and 1% penicillin/strepto-
mycin (PEST, Invitrogen) at 37°C, 5% CO2.
For transient transfections, 7 × 105 HEK 293 T cells
were seeded in 6 well plates and transfected 24 h later
using Polyethylenimine (CellnTec) according to the
product protocol.
Treatments and synthesis of gp91-TAT
Cells were treated with various concentration of H2O2 (0–
0.5 mM) (Sigma), NAC (N-acetyl-L-cysteine) (0–5 mM)
(Sigma) or BSO (buthionine sulfoximine) (0–2 mM)
(Sigma). Apocynin, and α-tocopherol were used at a final
concentration of 50 μM and 1 μM, respectively. The NOX
complex inhibitor peptide gp91ds-TAT ([H]-R-K-K-R-R-
Q-R-R-R-C-S-T-R-I-R-R-Q-L-NH2) and the control peptide
Scramble-TAT ([H]-R-K-K-R-R-Q-R-R-R-C-L-R-I-T-R-Q-
S-R-NH2) has been previously described [33] and wereused at a concentration of 10 μM. The peptides were
synthesized (SYRO multiple peptide synthesizer, Multi-
SynTech, Germany) on Fmoc-Rink- amide-chemmatrix
resin (PCAS biomatrix inc.) using standard Fmoc solid-
phase peptide synthesis. The peptide was cleaved using
95% TFA/2% water/2% triisopropylsilane/1% 1,2-ethane-
dithiol) for 3 h and precipitated in diethylether. The crude
peptide was dried in vacuum overnight. The peptide was
purified by HPLC on a DiscoveryW C-18 SupelcoW column
(Sigma-Aldrich, Sweden) using a gradient of acetonitrile/
water containing 0.1% TFA. Purity and identity was veri-
fied by analytical HPLC and by MALDI-TOF on aVoyager
STR. The mass-spectrum was acquired in positive ion re-
flector mode using a-cyano-4-hydroxycinnamic acid as
matrix (Sigma-Aldrich) (10 mg/ml, 7:3 acetonitrile: water,
0.1% TFA).
Cell lysis and Western blotting
Cell lysis and Western blotting was done as previously
described [28]. In brief, cells were lysed with RIPA buffer
(Millipore) supplemented with protease inhibitors and
the supernatant collected after centrifugation at 21,000 g
at 4 °C for 10 min. Protein concentrations were deter-
mined with Bradford assay (Bio-Rad) and 10–20 μg of
extract was subjected to SDS–PAGE. Proteins were
transferred onto nitrocellulose membrane (Whatman),
the membrane blocked and incubated with primary anti-
bodies in 2% milk-TBST (100 mM Tris-buffered saline
pH 7.4, 0.1% tween-20). Membranes were then washed,
incubated with secondary antibody in 2% milk-TBST,
and again washed with TBST. The protein of interest
was visualized using SuperSignal West Pico chemilumin-
escent substrate or SuperSignal West extended duration
substrate kits (Pierce) followed by film exposure or de-
tection by a ChemiDoc XRS+ imaging system (BioRad).
Primary antibodies were used at the following concen-
trations; Ataxin-7 [10] 1:700, actin 1:500 (SC-1616, Santa
Cruz), CAT 1:500 (SC-50508, Santa Cruz), SOD1 1:500
(SC-11407, Santa Cruz) and GSTA3 1:500 (gift from B.
Mannervik). Signal intensities of target bands were
quantified by Image lab software (BioRad). The relative
intensity of the target protein in control and treated
samples were acquired by first normalizing the target
band with the corresponding actin intensity. The nor-
malized intensity in control or treated samples was then
divided by the sum of the normalized intensities of the
target protein in control and all treated samples. The
quote for the control sample was set to 100% and all
treated samples in that experiment is shown as percent
compared to control.
Filter trap assay
Filter trap assay was done as previously described [28].
In short, cells were lysed in RIPA buffer and the pellets
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washed and resuspended in 50 μl DNAseI reaction buf-
fer containing four unit of DNaseI enzyme (EN0521,
Fermentas). The resuspended pellet, called the insoluble
fraction, was incubated at 37 °C for 1 hr and Bradford
assay (Bio-Rad) then used to determine the protein con-
centration in the sample. SDS and DTT were then added
to a final concentration of 2% and 100 mM respectively
before samples were heated at 95 °C for 5 min. Insoluble
fractions were loaded and vacuum filtered through a
0.2 μm pore size membrane using a Bio-Rad dot-blot ap-
paratus and a 0.1% SDS solution was added to each dot-
blot slots twice to wash. The membrane was then
removed from the dot-blot, blocked and subjected to im-
munoblotting using ATXN7 antibody as described
above. Following immunoblotting, signal intensities of
ATXN7 dots were quantified by Image lab software
(BioRad) and normalized against the protein concentra-
tions. For quantification of aggregation levels the average
intensity from each dot was divided by the sum of the
intensities of ATXN7 from all time points in that experi-
ment and the intensity from the untreated control sam-
ple was set to 100%. All treated samples in that
experiment is shown as percent compared to control.
Measuring of total ROS levels
FLQ10 or FLQ65 cells grown without Dox for 0, 2, 5, 8
or 11 days were seeded into 96-well culture plates in trip-
licate and grown in –Dox media for another 24 h before
ROS was measured. Cells grown with doxycyline were
used as control. ROS levels were measured by the
oxidation-sensitive probe, dichloro-fluorescein-diacetate
(DCHF-DA) (Sigma). Briefly, cells were washed two
times with PBS after which PBS containing DCFH-DA
(10 mM) was added to three wells with cells, whereas
PBS only was added to three control wells. Fluorimetric
measurement was taken immediately after addition for a
period of 30 min using a flex station II plate reader. Cells
treated with H2O2 (0.5 mM) were used as a positive con-
trol. The ROS levels were determined by subtracting the
fluorescence of the PBS only treated well from the fluor-
escence of the DCFH-DA treated well to remove any po-
tential background from GFP fluorescence.
Detection of mitochondria superoxide levels
FLQ65 cells grown without Dox for 5, 8 or 11 days were
seeded into 96-well culture plates in triplicates and
grown in –Dox media for another 24 h before mitochon-
dria superoxide was measured. Cells grown with dox
were used as control. Mitochondria superoxide levels
were measured by the oxidative sensitive probe, Mito-
SOX™ Red reagent (Sigma). Briefly, cells were washed
two times with PBS after which PBS containing Mito-
SOX™ Red reagent (5 μM) was added. Cells wereincubated for 30 min after which fluoremetric measure-
ment was taken for a period of 30 min using a flex sta-
tion II plate reader. Cells treated with Antimycin A (100
nM) were used as a positive control.
Cell viability/toxicity measurements
WST-1 viability assays (Clontech) were performed
according to the manufacturer’s protocol. Briefly, 50,000
induced or non-induced, treated or non-treated FLQ10
or FLQ65 PC12 cells were seeded in 96-well cell culture
plate 24 h before viability measurements. Ten μl of
WST-1 reagent was added to each well and after two
hours of incubation the absorbance (450–690 nm) was
measured on a Digiscan absorbance reader (Labvision).
Following the WST-1 assay the protein concentration in
each well was determined using Lowry assay (Bio-Rad).
The obtained cell viabilities were normalized by protein
concentration, and the value obtained from untreated
non-induced sample was set to 100%.
Membrane integrity as a measure of toxicity was
determined by analysis of lactate dehydrogenase (LDH)
leakage from the cytosol of damaged cells using the
CytoTox-ONE™ homogeneous membrane integrity assay
(Promega), according to the manufacturer’s protocol.
Briefly, 50,000 induced or non-induced cells were seeded
in 12-well cell culture plate 24 h before analysis. Fifty μl
of media from each sample/well was transferred to 96
well plates and incubated at room temperature for
20 min. A hundred μl of CytoTox-ONE (Promega) re-
agent was added to each sample and fluorescence mea-
sured using a flex station II plate reader at excitation
wavelength of 560 nm and emission wavelength of
590 nm.
GSH assay
GSH level was measured using the GSH kit (Promega).
Briefly, FLQ65 cells grown with or without Dox and
treated with 50 μM Apo for 9 days were washed 2 times
with PBS and lysed with GSH-Glo™ Reaction Buffer
(Promega) for 30 min. Lysates were diluted 1:15 in deio-
nized water and 10 μl of diluted lysate was transferred to
96-well plate in duplicates. Hundred μl of 1X GSH-Glo™
Reagent was added to each well and the samples incu-
bate for 30 min at room temperature before 100 μl of
prepared Luciferin Detection Reagent (Promega) was
added to each well. After a 15 min incubation the lumi-
nescence was read using a microplate luminometer (Pro-
mega). The obtained luminescence value was normalized
by protein concentration, and the value obtained from
untreated non-induced sample was set to 100%.
Statistical analysis
Statistical analysis was done by one-way ANOVA fol-
lowed by Tukey’s post-hoc test using Prism graph pad
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mean ± standard error of at least three independent
experiments. In all cases, P <0.05 was considered to be
statistically significant. Data are expressed as a percent-
age of control unless otherwise stated.
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